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It is well known that two major complications are mani- 
fested after any solid organ transplantation: rejection 
crisis due to immune conflict and infectious processes 
due to various agents (bacterial, viral, fungal). The 
question of exact and precise differentiation leads to 
adequate therapeutic decisions, because the proper 
immunosuppression would tend to preserve the rejected 
organ, but from the other hand, would interfere with the 
infection, if clinically manifested. The prediction of any 
of both complications gives a chance to overcome the 
clinical problem before its full development. Our model 
of a dynamic immunologic monitoring allows a precise 
differentiation and prognosis of the forthcoming com- 
plications after renal allotransplantation. The individuals 
studied are 54 recipients of renal allografts plus a control 
group of 24 hemodialysis patients, altogether 78. The 
methods included in this study are immunologic and 
microbiologic. The immunologic monitoring (T-helper 
and T-suppressor test and ratio-index; RBT, macrophage 
activity NBT-test, enzymatic activity SDH, alpha- 
GPDH, LDH; CIC; complement C3; NK-cell activity; 
warm and cold anti-T and anti-B antibodies; thin-needle 
aspiration biopsy morphologic analysis) is dynamically 
performed before and after transplantation and is applied 
very successfully for differentiation and prediction of 
both, rejection and infections (see our previous studies). 
The microbiologic analysis includes both, bacterial 
and viral, examinations to find out the actual cause of 
the infectious process. It is established that the following 
bacteria could be etiologic factors postoperatively: 
E. coli, Enterobacter, S. aureus, S. epidermidis, Pseudo- 
monas, Proteus, Klebsiella, E. faecalis, and Acinetobacter. 
As the bacterial origin of the infections is not our aim in 
this study, we neglect those agents: 65% of all post- 
transplantation infections. The virology analysis shows 
that 32% of all infections postoperatively are with viral 
origin: CMV, Hep. B and Hep. C virus, influenza virus, 
HIV The other 3% of the infections are from fungal 
origin (also out of our research plans at the moment). 
The results show that 21 cases (32%) are with viral 
infections: CMV - 8 (38%), HepB - 4 (19%), HepC -3 
(14%), Influenza - 5 (24%), HIV - 1 (5%), but 4 cases 
have a mixed infection: CMV+Influenza (2), CMV+ 
Hep+HIV (l), Influenza+Hep (1). The duration of the 
viral complications is 1.5 times longer than the bacterial 
ones. Two of the recipients with viral infections have a 
lethal issue: 1 with HIV (mixed with CMV+Hep) and 
1 with CMV (mixed with Influenza). Over 80% of all 
viral complications are clinically manifested in patients 
treated with cyclosporine and under 20% are in recipients 
without current cyclosporine therapy. The hemodialysis 
patients (24) show a prevalence of Hep-infections and 
2/3 of the cases are HepC. The immunologic monitoring 
definitely helps to predict and differentiate the immune 
conflict and rejection, as one of the two major com- 
plications after renal allotransplantation, and the 
infection, as a second one. From the other hand, the viral 
processes and the manifested immunodefficiency, alone 
or in combination, require a thorough analysis, exact 
diagnosis and individual therapeutic scheme. 
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Measles vaccination has been recommended after the 
second year following BMT, for patients not receiving 
immunosuppression. During a measles outbreak that 
irrupted in the city of SBo Paulo in 1997, we started 
measles vaccination for all patients after the first year of 
transplantation and conducted a prospective trial to 
evaluate the safety, effectiveness and sustained 
immunity after early measles vaccination. Patients 
received attenuated virus measles vaccination on day 
+365. Measles antibodies were detected by ELISA in 
serum samples taken on months 0,2,6,12 and 24 after 
vaccination. Thirty seven BMT recipients (5 ABMT, 
32 ALO) were evaluated. No severe or moderate 
adverse reactions was noted. Nine patients (24.3%) were 
susceptible (IgG 2 100 mUI/mL) at vaccination and all 
of them seroconverted. In patients considered immune 
at vaccination, a four fold rise in IgG titers was observed 
in only one of 24 patients (4.1%) with IgG ~200 
mUI/mL as compared to three of 4 patients (75%) with 
lOOcIgG<200 mUI/mL (p=O.O012), supporting that 
higher titers avoid wild or vaccine virus replication. 
Survival analysis showed a 96.4%, 86% and 60.2% 
probabilities of sustained measles immunity at 12,18 and 
24 months after early measles vaccination, respectively. 
Patients with IgG titers between 200 and 500 mUI/mL 
at vaccination were less likely to retain measles 
immunity 12 months after vacciantion as compared to 
those with IgG titers 2500 mUI/mL (p=O.Ol). The 
former patients should be screened more frequently for 
measles antibodies during follow-up. We concluded that 
measles vaccination on day +365 is safe and effective in 
BMT recipients and can be recommended in countries 
that did not achieved measles elimination. Booster doses 
of measles vaccine should be recommended only in 
patients with IgG titers <200mUI/mL. 
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